p.93 抽出テキスト

409. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585–93. https://doi.org/10.1056/NEJMoa1210356 410. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395–405. https://doi.org/10.1056/ NEJMoa1306687 411. Thibault B, Harel F, Ducharme A, White M, Ellenbogen KA, Frasure-Smith N, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation 2013;127: 873–81. https://doi.org/10.1161/CIRCULATIONAHA.112.001239 412. Merkely B, Hatala R, Wranicz JK, Duray G, Foldesi C, Som Z, et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial. Eur Heart J 2023;44:4259–69. https://doi.org/10.1093/ eurheartj/ehad591 413. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 2002;288:3115–23. https://doi.org/10.1001/jama. 288.24.3115 414. Merkel E, Hatala R, Szigeti M, Schwertner W, Lakatos B, Behon A, et al. Upgrading right ventricular pacing to cardiac resynchronization in HFrEF patients improves symptoms and functional outcomes. JACC Heart Fail 2025; 13:265–73. https://doi.org/10.1016/j.jchf.2024.09.011 415. Leyva F, Zegard A, Patel P, Stegemann B, Marshall H, Ludman P, et al. Timing of cardiac resynchronization therapy implantation. Europace 2023;25: euad059. https://doi.org/10.1093/europace/euad059 416. Goldstein SA, Mentz RJ, Hellkamp AS, Randolph TC, Fonarow GC, Hernandez A, et al. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clin Cardiol 2019; 42:256–63. https://doi.org/10.1002/clc.23135 417. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015;101:1800–6. https://doi.org/10.1136/ heartjnl-2015-307634 418. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468–76. https://doi.org/10.1016/j.jacc.2010.11.030 419. Cannon JA, Collier TJ, Shen L, Swedberg K, Krum H, Van Veldhuisen DJ, et al. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2015;17:707–16. https://doi.org/ 10.1002/ejhf.303 420. Huang HT, Huang JL, Lin PL, Lee YH, Hsu CY, Chung FP, et al. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy. ESC Heart Fail 2022;9:3825–35. https://doi.org/10.1002/ehf2.14107 421. Straw S, McGinlay M, Gierula J, Lowry JE, Paton MF, Cole C, et al. Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. J Cardiovasc Med (Hagerstown) 2021;22:848–56. https://doi. org/10.2459/JCM.0000000000001231 422. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, et al. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2018;71:306–17. https://doi.org/10.1016/j.jacc.2017.11.020 423. Wang NC, Singh M, Adelstein EC, Jain SK, Mendenhall GS, Shalaby AA, et al. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guidelinedirected therapies: the NEOLITH study. Heart Rhythm 2016;13:933–42. https://doi.org/10.1016/j.hrthm.2015.12.020 424. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015;36:1983–9. https://doi.org/10.1093/eurheartj/ehv242 425. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM, Carpenter JL, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014;174:1340–8. https://doi.org/10.1001/jamainternmed.2014. 2717 426. Glikson M, Burri H, Abdin A, Cano O, Curila K, De Pooter J, et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace 2025;27: euaf050. https://doi.org/10.1093/europace/euaf050 427. Vinther M, Risum N, Svendsen JH, Mogelvang R, Philbert BT. A randomized trial of His pacing versus biventricular pacing in symptomatic HF patients with left bundle branch block (His-Alternative). JACC Clin Electrophysiol 2021;7:1422–32. https://doi.org/10.1016/j.jacep.2021.04.003 428. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, et al. Long-term outcomes of His bundle pacing in patients with heart failure with left bundle branch block. Heart 2019;105:137–43. https://doi.org/10.1136/heartjnl-2018-313415 429. Abdin A, Werner C, Burri H, Merino JL, Vukadinovic D, Sawan N, et al. Outcomes of left bundle branch area pacing compared to His bundle pacing as a primary pacing strategy: systematic review and meta-analysis. Pacing Clin Electrophysiol 2023;46:1315–24. https://doi.org/10.1111/pace.14836 430. Frausing M, Baek AL, Kristensen J, Gerdes C, Nielsen JC, Kronborg MB. Long-term follow-up of selective and non-selective His bundle pacing leads in patients with atrioventricular block. J Interv Card Electrophysiol 2023;66: 1849–57. https://doi.org/10.1007/s10840-023-01488-x 431. Graterol FR, Pujol-Lopez M, Borras R, Ayala B, Uribe L, Guasch E, et al. Predictors of failed left bundle branch pacing implant in heart failure with reduced ejection fraction: importance of left ventricular diameter and QRS morphology. Heart Rhythm 2024;21:2571–8. https://doi.org/10.1016/j. hrthm.2024.06.019 432. Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, et al. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol 2022;80:1205–16. https://doi.org/10.1016/j.jacc.2022.07. 019 433. Vijayaraman P, Zalavadia D, Haseeb A, Dye C, Madan N, Skeete JR, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. Heart Rhythm 2022;19:1263–71. https://doi.org/10.1016/j.hrthm.2022.04.023 434. Mullens W, Dauw J, Gustafsson F, Mebazaa A, Steffel J, Witte KK, et al. Integration of implantable device therapy in patients with heart failure: a clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2024;26:483–501. https://doi.org/10. 1002/ejhf.3150 435. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace 2021;23:1324–42. https://doi.org/10.1093/europace/euaa411 436. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;367:2275–83. https://doi.org/10.1056/NEJMoa1211107 437. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013;309:1903–11. https://doi.org/10.1001/jama.2013.4598 438. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail 2018;6:874–83. https://doi. org/10.1016/j.jchf.2018.04.010 439. Linde C, Grabowski M, Ponikowski P, Rao I, Stagg A, Tschope C. Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM-HFpEF). Eur J Heart Fail 2022;24:2275–84. https://doi.org/10.1002/ejhf.2619 440. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015;3:487–96. https://doi.org/ 10.1016/j.jchf.2015.02.006 441. Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, et al. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: long-term outcomes. Eur J Heart Fail 2024;26:1051–61. https://doi.org/10.1002/ejhf.3232 442. Stone GW, Lindenfeld J, Rodes-Cabau J, Anker SD, Zile MR, Kar S, et al. Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial. Circulation 2024;150:1931–43. https://doi.org/10.1161/CIRCULATIONAHA. 124.070870 443. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, shamcontrolled trial. Lancet 2022;399:1130–40. https://doi.org/10.1016/ S0140-6736(22)00016-2 444. Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026